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Genetic polymorphisms in Solute carrier family 1 (glial high affinity glutamate transporter), member 2 (SLC1A2)
have been linked with essential tremor. SLC1A2 encodes excitatory amino acid transporter type 2 (EAAT2), which
clears glutamate from the synaptic cleft. One postulated mechanism for essential tremor is the over-excitation of
glutamatergic olivo-cerebellar climbing fibers, leading to excitotoxic death of Purkinje cells. Other glutamatergic
excitatory signals are transmitted to Purkinje cells via parallel fibers of cerebellar granule neurons. Therefore, the
expression level of glutamate transporters could be important in essential tremor pathogenesis. Using Western
blotting, we compared the expression levels of the two main glutamate transporters in the cerebellar cortex, EAAT1
and EAAT2, in postmortem tissue from 16 essential tremor cases and 13 age-matched controls. We also studied the
localization of EAAT1 and EAAT2 using immunohistochemistry in 10 essential tremor cases and 12 controls. EAAT1
protein levels were similar in cases and controls (1.12 ± 0.83 vs. 1.01 ± 0.69, p =0.71) whereas EAAT2 protein levels
in essential tremor cases were only 1/3 of that in controls (0.35 ± 0.23 vs. 1.00 ± 0.62, p < 0.01). Interestingly,
EAAT2, but not EAAT1, was expressed in astrocytic processes surrounding the Purkinje cell axon initial segment, a
region of previously observed pathological changes in essential tremor. Our main finding, a significant reduction
in cerebellar cortical EAAT2 protein levels in essential tremor, suggests that Purkinje cells in essential tremor might
be more vulnerable to excitotoxic damage than those of controls.
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Essential tremor (ET) is a prevalent neurological disease
marked by a persistent 4-12 Hz action tremor in the
arms [1]. ET has a strong genetic component, as ET pa-
tients often have a family history of tremor, and twins
with ET are highly concordant for disease status [2]. Re-
cently, polymorphisms in the solute carrier family 1
(glial high affinity glutamate transporter), member 2
(SLC1A2) gene have emerged as a potential genetic risk
factor for ET in a genome-wide association study in
Europe [3]. While this association was subsequently
confirmed in two Asian cohorts [4,5], another study did
not show an association [6], and a meta-analysis revealed
conflicting results [7]. Given this evolving picture, the
SLC1A2 gene remains of considerable interest. The
SLC1A2 gene encodes excitatory amino acid transporter 2* Correspondence: sk3295@columbia.edu
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unless otherwise stated.(EAAT2), which is a protein that is critical for maintaining
glutamate levels in the synaptic cleft in the adult brain [8].
Glutamatergic synapses are the major excitatory synap-
ses in the brain, and brain glutamate levels are exquisitely
controlled [8]. Excessive extracellular glutamate, due to
over-excitation of neurons or failure of glutamate recyc-
ling, can lead to mitochondrial dysfunction and subse-
quent neuronal death. This mechanism of “excitotocity”
has been implicated to be of potential patho-mechanistic
importance in epilepsy, stroke, and amyotrophic lateral
sclerosis [9-11]. Extracellular glutamate levels are mainly
regulated by a family of glutamate transporters, the excita-
tory amino-acid transporters (EAATs), which in the cen-
tral nervous system comprise five subtypes (EAAT1 - 5)
[12]. Both EAAT1 and EAAT2 are expressed predomin-
antly in astrocytes, the major cell type responsible for
glutamate uptake [13]. EAAT1 is expressed during devel-
opment and also in adulthood, whereas EAAT2 is the
main glutamate transporter in adult brain, responsible
for over 90% of total glutamate uptake [8,12]. EAAT3,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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and may play a role in neuronal excitability [8].
Clinical and neuroimaging evidence has pointed to the
importance of the cerebellum in the pathogenesis of ET
[14]. Postmortem studies have revealed a broad range of
structural changes in the cerebellum in ET. These include
Purkinje cell (PC) loss in some studies [15,16], but not in
the others [17,18]. One hypothesized mechanism for ET is
that it is a disorder of over-excitation of glutamatergic
olivo-cerebellar climbing fibers, which results in excito-
toxic damage to PCs. Alterations in EAAT levels in the
cerebellar cortex could result in a breakdown in normal
extracellular glutamate homeostasis, enhancing vulner-
ability to excitotoxic damage. Since EAAT1 and EAAT2
are the two major glutamate transporters in the cerebellar
cortex, we systematically investigated the expression level
and immunohistochemical cellular localization of these
two proteins in the postmortem cerebellum of ET cases
vs. controls.
Materials and methods
Brain repository and study subjects
The study was conducted at the Essential Tremor Central-
ized Brain Repository (ETCBR), New York Brain Bank
(NYBB), Columbia University, New York. Post-mortem
tissue was obtained from ET cases and age-matched non-
diseased controls, as previously described [19].
The clinical diagnosis of ET was initially assigned by
treating neurologists, and then confirmed by an ETCBR
study neurologist using medical records, study question-
naires, a detailed videotaped neurological assessment, and
ETCBR diagnostic criteria [20]. The study question-
naires included data on family history of tremor and
medications (Additional file 1: Table S1). The neurolo-
gist (EDL) reviewed all videotaped neurological exami-
nations and rated the severity of postural and kinetic
(pouring, drinking, using spoon, drawing spirals, finger-
nose-finger) arm tremors (ratings =0 - 3), resulting in a
total tremor score (range =0 to 36 [maximum]) [21].
The presence of head or voice tremor on examination
was noted in each patient. None of the ET cases or con-
trols had a history of traumatic brain injury or heavy
ethanol use, as previously defined [22]. Non-diseased
control brains were obtained from the NYBB and were
from individuals followed at the Alzheimer disease (AD)
Research Center or the Washington Heights Inwood
Columbia Aging Project at Columbia University. They
were followed prospectively with serial neurological
examinations, and were clinically free of AD, ET,
Parkinson’s disease, Lewy body dementia, or progres-
sive supranuclear palsy.
We selected available age-matched, non- diseased
control brains from NYBB based on age at death.
Therefore, cerebellar cortical tissue was available forimmunohistochemistry on 10 ET cases and 12 controls
with a similar age distribution, and for Western blot
analyses on 16 ET cases and 13 controls with a similar
age distribution. There was available banked tissue for
both Western blot and immunohistochemistry experi-
ments in 8 ET brains and 9 control brains.
As previously described, all ET and control brains had
a complete neuropathological assessment at the NYBB
[19]. Brains had standardized measurements of brain
weight (grams), postmortem interval (PMI, hours be-
tween death and placement of brain in a cold room or
upon ice). We excluded ET cases with Lewy body path-
ology (α-synuclein staining).
A standard 3 × 20 × 25 mm parasagittal neocerebellar
block was obtained from a 0.3-cm-thick parasagittal
slice located 1 cm from the cerebellar midline. Paraffin
sections (7 um thick) were stained with Luxol fast blue
hematoxylin and eosin (LH&E) or Bielschowsky silver
methods as described previously [15]. Axonal torpedoes
were quantified in the entire LH&E-stained section.
Cerebellar immunohistochemistry
Seven-μm-thick paraffin-embedded cerebellar sections
were incubated with polyclonal goat anti-EAAT1 anti-
body (Santa Cruz, sc-7758, 1:1000) or guinea pig anti-
EAAT2 antibody (Millipore, ab1783, 1:200) at 4°C for
24 hours after antigen retrieval in Trilogy (Cell
Marque) in a vegetable steamer for 60 minutes, 100°C.
The sections were incubated with goat anti-rabbit
(Fisher Scientific, 1:200) or anti-guinea pig IgG biotin-
conjugated antibody (Millipore, 1:200), respectively,
followed by 3,3′-diaminobenzidine (DAB) precipita-
tion. We tested the immunohistochemical specificity
of both EAAT1 antibody and EAAT2 antibody using
EAAT1 or EAAT2 peptide block (EAAT1 peptide from
Santa Cruz, sc-7758P, and EAAT2 peptide from Tocris
Bioscience, 2128). For peptide block experiments, pep-
tides and antibodies at 10:1 molar ratio or antibodies
alone were incubated at 4°C for 24 hours and were
then used as the primary antibody for immunohisto-
chemistry. Microscopic images of immunohistochemi-
cally stained sections were obtained by bright field
microscopy (Zeiss). EAAT2 immunopositive staining
intensity in the cerebellar cortex was quantified in
DAB-light microscopic cerebellar sections, and all
EAAT2 immunohistochemistry was performed in the
same batch with identical time of DAB precipitation.
Automatic slide scanning was performed in each case
and the intensity of EAAT2 immunoreactivity was mea-
sured with Leica Beiosystems Tissue IA Software, version
2.0. The intensity of EAAT2 immunoreactivity in the cere-
bellar cortex was normalized to that in the cerebellar
white matter. All morphological measurements were per-
formed by a rater (ML) blinded to the diagnosis, with a
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acter covering the identification number on each slide,
and random ordering of ET case and control specimens
within the alphabetic blinded code.
For dual immunofluorescence studies, we labeled
paraffin-embedded sections with anti-EAAT1 antibodies
or anti-EAAT2 antibodies and mouse anti-glutamine
synthetase (BD Transduction, 610518, 1:300), mouse anti-
glial fibrillary acidic protein (GFAP) (Sigma G3893,
1:100), or rabbit anti-Lingo-1 antibody (Millipore, 07-
678, 1:100). The secondary antibodies were goat anti-
rabbit antibodies conjugated with Alexa fluorophore
488 or goat anti-mouse antibodies conjugated with
Alexa fluorophore 594 (All Invitrogen, 1:100). Micro-
scopic images were obtained by confocal microscopy
(Leica).Western blot analysis
Frozen cerebellar cortex in standardized vials was sol-
ubilized in RIPA buffer (Sigma) with proteinase inhibi-
tors (Roche Diagnostics) and phosphatase inhibitors
(Sigma) and was sonicated followed by centrifugation
at 14,000 g for 10 minutes. Proteins (50μg; Bradford
assay) were separated on a NuPAGE Novex 4–12% Gel
(Invitrogen) and transferred to a PVDF membrane
(Millipore). Blots were incubated with polyclonal anti-
bodies against EAAT2 (Millipore, ab1783, 1:2000),
EAAT1 (Santa Cruz, sc-15316, 1:1000), GFAP(Sigma
G3893, 1:25,000) and monoclonal mouse antibody
against β-actin (Abcam, ab6276, 1:5000) followed by
secondary IR-Dye 800CW donkey anti-guinea pig IgG
antibody (Licor 1:10,000) or anti-mouse IgG antibody
(Licor 1:20,000). The signals were visualized with a LI-
COR Infrared Odyssey Scanner (LI-COR Biosciences,
Lincoln, NE). Signal intensities were analyzed with
Odyssey 2.1 software package by a rater (ML) blinded
to the diagnosis. The signals of EAAT1 and EAAT2
were normalized to β-actin signals for each sample.
Two sets of Western blots were repeated to obtain an
average ratio of protein to β-actin value for each sam-
ple, expressed as relative to that of controls, arbitrarily
set at 1.0. We also tested the specificity of EAAT1 and
EAAT2 antibodies on Western blot using the peptide
block method described above.Genotyping
We extracted DNA from frozen human brains using
QIAamp DNA Mini kit (Qiagen) and we amplified the
region containing rs3794087, an intronic variant of
SLC1A2, by polymerase chain reactions (PCRs) using
published primer sequences [4]. The PCR fragments
were sent for commercial sequencing to determine the
genotype of rs3794087.Data analyses
Data were analyzed in SPSS (v.21). All the continuous
measures analyzed in this study were normally distrib-
uted. Demographic and clinical characteristics of ET
cases and controls were compared using Student’s t –
tests and Chi-square tests. For non-parametric compar-
isons, we used Mann-Whitney tests. Pearson’s correlation
coefficients were used to assess correlations between con-
tinuous measures that were normally distributed. Spear-
man’s rank correlation coefficient was used to assess
correlations between measures that were not normally
distributed. We also used two-way ANOVA to analyze the
EAAT2 levels in ET cases and controls with different
rs3794087 genotypes.Results
ET cases and controls
ET cases and controls had similar ages, gender, brain
weights, PMI, and CERAD plaque scores. ET cases had
higher PC axonal torpedo counts and a lower number of
PCs (Table 1). All ET cases had tremor onset prior to
age 65 years.Specificity of EAAT1 and EAAT2 antibodies
We first assessed the specificity of EAAT1 antibody on
Western blot and immunohistochemistry. EAAT1 anti-
body labeled a major 64 kDa band on Western blot, con-
sistent with prior reports on EAAT1 using post-mortem
human brain tissue [23,24]. The multimeric form of
EAAT1 (190 kDa) and the differential glycosylation
form of EAAT1 (97 kDa), which we observed, has also
been noted by others [23,24]. A 55 kDa band of EAAT1
can represent the alternative spliced form of EAAT1
(Additional file 2: Figure S1A) [25]. Pre-incubation of
EAAT1 antibody with EAAT1 peptide completely blocked
all immunoreactive bands on Western blot. EAAT1 anti-
body also strongly labeled cerebellar cortex, and this
immunoreactivity was entirely blocked by pre-incubation
with EAAT1 peptide (Additional file 2: Figure S1B).
Next, we determined the specificity of EAAT2 anti-
body. EAAT2 antibody labeled a 55 kDa band on West-
ern blot, consistent with prior studies (Additional file 3:
Figure S2A) [23,24]. Several other studies have reported a
slightly higher molecular weight (~60 kDa) for EAAT2,
which might be due to differential splicing and/or glycosyl-
ation [24,26,27]. We also observed faint labeling of much
higher molecular weight bands, suggesting that EAAT2
also forms multimers, as previously described (Additional
file 3: Figure S2A) [23,24]. The EAAT2 antibody also la-
beled a similar 55 kDa band in a human cerebral cortical
lysate (Additional file 3: Figure S2B). Pre-incubation of
EAAT2 antibody with EAAT2 peptide robustly eliminated
the EAAT2 band on Western blot (Additional file 3:
Table 1 Clinical and pathological features of ET cases and control
Western blot analysis Immunohistochemistry
ET Controls ET Controls
n 16 13 10 12
Age at death (years) 83.6 ± 5.5 79.7 ± 7.1 85.7 ± 5.9 81.5 ± 6.4
Female gender 11 (68.8%) 8 (61.5%) 8 (80.0%) 10 (83.3%)
Age of tremor onset 30.9 ± 21.4 NA 42.0 ± 30.5 NA
Disease duration 53.4 ± 26.0 NA 44.3 ± 31.8 NA
Total tremor scores 23.8 ± 10.5 NA 24.8 ± 12.9 NA
Presence of head tremor 9 (56.3%) NA 8 (80.0%) NA
Presence of voice tremor 4 (25.0%) NA 4 (40.0%) NA
Family history of tremor 8 (50.0%) NA 8 (80.0%) NA
Brain weight (grams) 1170 ± 155 1181 ± 173 1138 ± 192 1174 ± 140
Postmortem interval (hours) 3.2 ± 4.7 5.9 ± 2.7 3.5 ± 5.8 9.7 ± 10.6
Axonal torpedoes 22.1 ± 20.7** 4.6 ± 7.7 12.7 ± 9.8** 6.8 ± 4.3
Purkinje Cell Count 6.5 ± 1.6** 10.2 ± 2.3 7.1 ± 1.6* 9.4 ± 2.2
*p < 0.05.
**p < 0.01.
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histochemistry (Additional file 3: Figure S2D).
To assess possible cross-reactivity between EAAT1 and
EAAT2 antibodies, we performed EAAT1 peptide block
with EAAT2 antibody and we found that EAAT1 peptide
did not diminish EAAT2 immunohistochemical labeling
(Additional file 3: Figure S2E). These results demonstrated
the specificity of both EAAT1 and EAAT2 antibodies.
Since the higher molecular weight multimers of EAAT1
and EAAT2 were not consistently detected, we analyzedFigure 1 Decreased EAAT2 protein levels in essential tremor (ET) cere
and β-actin (A) from cerebellar cortex of 16 ET cases and 13 controls. EAAT
between ET cases and controls (B). EAAT2 protein levels were significantly
EAATs is expressed relative to control brains, which was arbitrarily set at 1.0the predominant strongly staining monomers of EAATs
on Western blots.
Decreased EAAT2 levels in ET cerebellum
We quantified EAAT1 and EAAT2 protein levels in the
cerebellar cortex of ET cases and controls by Western
blot. We found that EAAT1 levels in the cerebellar cortex
were similar in ET cases and controls (1.12 ± 0.83 in ET
cases vs. 1.01 ± 0.69 in controls, p = 0.71) (Figure 1A, B).
By contrast, EAAT2 levels in ET cases were only 1/3 ofbellar cortex. Representative Western blots of EAAT1, EAAT2, GFAP,
1 protein levels, normalized to a β-actin loading control, were similar
decreased in ET cases compared to controls (C). The fold-change in
. Mean ± SEM were shown.
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0.62 in controls, p <0.001) (Figure 1A, C). To further in-
vestigate that the decrease in EAAT2 levels was not due
to a general decrease in astrocytic proteins, we assessed
the levels of another astrocytic protein: GFAP (Figure 1A).
GFAP levels were similar in ET cases and controls (1.13 ±
0.33 in ET cases vs. 1.00 ± 0.22 in controls, p =0.26). We
also normalized EAAT2 levels to GFAP levels in ET
cases and controls, and we found that ET cases still had
less than half the EAAT2 levels compared with controls
(0.44 ± 0.52 in ET cases vs. 0.94 ± 0.80 in controls, p =0.02).
EAAT2 protein levels were positively correlated with
PC counts (Pearson’s correlation coefficient r = 0.53, p =
0.004, i.e., individuals with lower EAAT2 levels had
lower PC counts) (Additional file 4: Figure S3). EAAT2
levels tended to inversely correlate with torpedo counts;
however, the association was only modest and did not
reach statistical significance (r = -0.21, p =0.28). We fur-
ther explored that whether EAAT2 levels were related to
medication use. We found that EAAT2 levels did not
differ between ET cases treated with and without pro-
pranolol (0.36 ± 0.23 vs. 0.42 ± 0.31, p =0.86), or treated
with and without GABAergic medications (primidone orFigure 2 Decreased intensity of EAAT2 immunohistochemistry in ET c
EAAT2 antibody were scanned and the intensity of immunostaining of the
randomly selected white matter regions. We found a significant decrease in
0.5 mm. Ctrl = control.benzodiazepines) (0.32 ± 0.22 vs. 0.46 ± 0.29, p =0.36).
None of the ET patients took glutamatergic medications
such as topiramate. EAAT2 levels did not correlate with
the number of ET medications (i.e. propranolol and pri-
midone) (Spearman’s r = -0.33, p =0.11) or with the
number of all medications (Pearon’s r = -0.02, p =0.95),
suggesting that medication use alone could not account
for the EAAT2 levels. EAAT2 levels did not correlate
with the disease duration (Pearson’s r =0.19, p =0.50) or
total tremor scores (r =0.32, p =0.27).
In the immunohistochemistry study, ET cases also
had decreased EAAT2 levels when compared to con-
trols (0.60 ± 0.25 in ET cases vs. 1.00 ± 0.41 in controls)
(Figure 2A-C). The levels of EAAT2 on the Western blot
correlated with those from EAAT2 immunohistochemis-
try (Pearson’s correlation coefficient r =0.62, p <0.01).
We also determined the genotypes of rs3794087 in ET
cases and controls, although the number of subjects was
too small to subject these analyses to statistical testing.
We found that 50% of ET cases and 84.6% of controls had
GG genotypes, 37.5% of ET cases and 15.4% of controls
had GT genotypes, and 12.5% ET cases and no controls
had TT genotypes (Additional file 5: Figure S4A). ET caseserebellar cortex. Paraffin-embeded sections immunolabeled with
cerebellar cortex was quantified. The intensity was normalized to the
EAAT2 immunoreactivity in the ET cerebellar cortex (A-C). Scale bar
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decreased EAAT2 levels than controls with the same
genotypes (two way ANOVA, p <0.05 and p <0.01, re-
spectively) (Additional file 5: Figure S4B).
EAAT protein localization in cerebellar cortex
We next investigated the cellular distribution of EAAT1
and EAAT2 proteins in the cerebellar cortex. We did
not observe different expression patterns of EAAT1 and
EAAT2 in ET cases and controls. Immunolabeling of
EAATs in paraffin-embedded cerebellar cortical sections
revealed that EAAT1 was expressed predominantly in
the Bergmann glia radial processes in the molecular and
far less so in the granule cell layer (Figures 3A, B; 4A,
D). EAAT2 was distributed both in the glial processes in
the molecular layer and also in the bushy astrocytes res-
iding in the granule cell layer (Figures 3C, D; 4J, M),
consistent with a previous report [28].
We performed dual immunoflourescence labeling of
EAAT1 and EAAT2, and astrocytic markers, GFAP or glu-
tamine synthetase, in the cerebellar cortex of ET cases and
controls (Figure 4A-F, J-O). Both EAAT1 and EAAT2Figure 3 EAAT expression in the cerebellar cortex. Immunohistochemi
EAAT1 was expressed predominantly in the Bergmann glia radial processes
processes in the molecular layer and in the bushy astrocytes in the granula
EAATs (A-D). EAAT2 was also enriched in the astrocytic processes surround
g: granule cell layer, p: PC body. Scale bar 25 μm.appeared to be puncta along the GFAP- positive astrocytic
processes (Figure 4G-I, P-R), showing that GFAP and
glutamine synthetase were expressed predominantly in
the cell bodies and proximal processes of astrocytes
whereas EAATs were expressed in the end feet of the astro-
cytic processes [28]. There was stronger co-localization of
EAAT1 and astroctyic markers in cytoplasm of Bergman
glial cell soma than observed with EAAT2, consistent
with greater expression of EAAT1 than EAAT2 in Berg-
mann glia, as previously described [29]. The EAAT2 ex-
pression in the granule cell layer extensively colocalized
with glutamine synthetase and GFAP. These studies
confirmed that EAAT1 and EAAT2 were expressed in
astrocytic processes in the cerebellar cortex.
EAAT2 and the PC axonal initial segment (AIS)
In our postmortem studies of ET, we have identified
several abnormal pathological features that are in
proximity to the PC AIS, including torpedoes, “hairy”
baskets, and elongated Lingo-1 labeled basket cell pin-
ceaus [15,30,31]. The PC AIS is surrounded by astro-
cytic processes in addition to basket cell pinceau [32].stry with anti-EAAT1 or anti-EAAT2 antibody in the cerebellar cortex.
in the molecular layer (A, B). EAAT2 was expressed in the glia radial
r cell layer (C, D). Purkinje cell and granule cell bodies did not express
ing the PC axonal initial segment (D, arrows) m: molecular layer,
Figure 4 (See legend on next page.)
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Figure 4 EAATs colocalized with astrocytic markers. Dual immunofluorescence labeling of ET cerebellar cortex with anti-EAAT1 or anti-EAAT2
(Alexa 488, green, A, D, G, J, M, P), anti-GFAP (Alexa 594, red, B, E, K, Q), and anti-glutamate synthetase (Alexa 594, red, E, N). Both EAAT1 and
EAAT2 partially colocalized with GFAP or glutamine synthetase in the cerebellar cortex (C, F, L, O). The cell bodies of Bergmann glia showed
stronger colocalization with EAAT1 than with EAAT2 (arrows, in D-F). Higher magnification images showed both EAAT1 and EAAT2 form puncta
along the GFAP-positive astrocytic processes (G-I, P-R). p: PC body. Scale bar 25 μm.
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cytic processes in this region and around torpedoes identi-
fied the granule cell layer. We first labeled basket cell
pinceau with Lingo-1 antibody and co-immunostained
with EAAT1 or EAAT2 antibodies. We observed that
EAAT2, but not EAAT1, labeled astrocytic processes in-
terdigitated with Lingo-1 labeled basket cell processes
(Figure 5A-F), suggesting that EAAT2 is the major glu-
tamate transporter in this region. In addition, some bushy
astroctyes in the granule cell layer showed stronger
EAAT2 staining, and their processes were visualized sur-
rounding PC axonal torpedoes and in close proximity to
the PC axon distal to the torpedo (Figure 5G-J).Discussion
SLC1A2 polymorphisms have been associated with ET
[3-5], and SLC1A2 encodes EAAT2, a major glutamate
transporter in the adult brain [12]. In the present study
of the postmortem cerebellar cortex, Western blot ana-
lysis demonstrated that EAAT2 levels were decreased
in ET cases compared to controls, whereas EAAT1 levels
were similar in ET cases and controls. EAAT1 and EAAT2
are expressed in astrocytes and interestingly, EAAT2, but
not EAAT1, was present in the astrocytic processes sur-
rounding the PC AIS, a site found to be particularly ab-
normal in prior studies of ET [15,30,31].
Functional astrocytes critically regulate glutamate levels
at the synapses, and the membrane-bound glutamate
transporters, EAAT1 and EAAT2, are important in this
recycling of glutamate [8]. Failure of glutamate reuptake
by astrocytes would lead to accumulation of glutamate in
the synaptic cleft and over-stimulation of glutamate recep-
tors. Over-excited neurons have elevated cytoplasmic cal-
cium levels, which subsequently triggers neuronal injury
or cell death [33]. This mechanism of excitotoxicity has
been implicated in many neurological disorders, includ-
ing epilepsy [9], stroke [10], amyotrophic lateral scler-
osis [11], AD [34], traumatic brain injury [35], multiple
sclerosis [36], and schizophrenia [23,24]. Interestingly,
in ET, rhythmic over-excitation of glutamatergic olivo-
cerebellar climbing fibers, which release glutamate onto
PCs, has been hypothesized to be of possible patho-
mechanistic importance, although this is purely hypo-
thetical [37]. With the down-regulation of EAAT2 in
the ET cerebellar cortex, the capacity of glutamate re-
uptake could be reduced.Our current results should not be over-interpreted.
They merely suggest that ET cerebella might be more vul-
nerable to excitotoxic damage than those of controls; they
do not directly demonstrate greater vulnerability, nor do
they show that there is excessive over-excitation derived
from glutamatergic olivo-cerebellar climbing fibers in ET.
EAAT2 levels correlated with PC counts but not tremor
scores or tremor duration, providing further support that
decreased EAAT2 levels in ET might cause excitotoxic PC
death and might not be the result of long-standing tremor.
Although climbing fiber - PC synapses in the molecular
layer have been postulated as the location of PC excito-
toxicity in ET [38], other glutamatergic synapses located
more broadly throughout the cerebellar cortex, including
parallel fiber-PC synapses, mossy fiber-granule neuron
synapses, and climbing fiber collaterals to granule neurons
and Golgi cells should be considered, and insufficient
glutamate uptake in these synapses could result in
over-excitation. In other words, increased vulnerability
to excitotoxicity might not entirely be in the molecular
layer in ET cases.
There are other possible explanations for our find-
ings. One other explanation is that decreased EAAT2
levels also could be a secondary phenomenon due to the
long-standing tremor in the olivo-cerebello-thalamic loop.
Interestingly, harmine, a natural β-alkaloid that can induce
ET-like tremor in animal models, can also alter the levels
of EAAT2 in cultured human astrocytes [39], raising the
possibility that the decreased EAAT2 levels could be the
result of defective β-alkaloid homeostasis in ET [40].
Most of the discoveries in ET pathology focus on PCs
[15,16]. In addition, structural changes in the region of
the PC AIS, and adjacent areas, are observed in ET;
these include torpedoes, “hairy” (i.e., hypertrophic) bas-
ket cell axonal processes, and elongated basket cell pin-
ceau [15,30,31]. The PC AIS is surrounded by basket cell
processes and astrocytic processes, and PC physiology is
actively regulated by these structures. The PC AIS is
critical for determining PC polarity and the timing of ac-
tion potential firing [41], and structural alterations in
this region thus might be directly related to ET. Two
genetic polymorphisms have been linked to ET, Lingo-1
and SLC1A2 [3,42,43]. Interestingly, we found that
Lingo-1 is enriched in the basket cell processes [31]
whereas EAAT2 is selectively expressed in the astrocytic
processes, both surrounding PC AIS. These two ET re-
lated proteins are enriched in this region, suggesting that
Figure 5 EAATs in astrocytic processes surrounding PC axonal initial segment (AIS) in the ET cerebellar cortex. Dual immunofluorescence
with anti-EAAT1 or anti-EAAT2 (Alexa 488, green) antibody and anti-Lingo-1 (Alexa 594, red) antibody in the region adjacent to PC AIS
(A-F). Basket cell pinceau were visualized with anti-Lingo-1 antibody. We found that only very low levels of EAAT1 were found in this region
(A-C, arrows). In contrast, EAAT2 positive astrocytic processes interdigitated with Lingo-1 positive basket cell processes, surrounding PC AIS (D-F, arrows).
Dual immunofluorescence with anti-EAAT2 (Alexa 488, green) and anti-Calbindin (Alexa 594, red) antibody to investigate the relationship between PC
axonal torpedoes and EAAT2-expressing astrocytic processes (G-I). EAAT2-expressing astrocytic processes surrounded a PC axonal torpedo
(Arrowheads, H-I). Immunohistochemistry with anti-EAAT2 antibody also revealed EAAT2-expressing astrocytic processes distributed around a
PC axonal torpedo (Arrowheads, J). p: Purkinje cell body, t: PC axonal torpedo. Scale bar 25 μm.
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http://www.actaneurocomms.org/content/2/1/157the PC AIS and surrounding regions could be important
in ET pathogenesis.
The limitation of the current study is that we focused
only in the cerebellar cortex. First, future studies will
need to elucidate whether EAAT2 levels are also altered
in other brain regions such as the cerebellar dentate nu-
cleus, thalamus and inferior olivary nucleus [44]. Also,there was available banked tissue for both Western blot
and immunohistochemistry experiments in 8 ET case
brains and 9 control brains; therefore, in some cases
and controls tissue was available for only one type of
experiment. Third, further studies to compare EAAT2
levels of ET cases with those of other tremor disorders
such as tremor predominant Parkinson’s disease would
Lee et al. Acta Neuropathologica Communications 2014, 2:157 Page 10 of 11
http://www.actaneurocomms.org/content/2/1/157be valuable. Finally, whether the down-regulation of
EAAT2 can lead to increased PC vulnerability to excito-
toxicity will need to be determined in future experiments.Conclusion
In summary, EAAT2 levels were significantly decreased
in the ET cerebellar cortex, in contrast to similar levels
of EAAT1 levels between ET cases and controls. ET
brains might be more vulnerable to excitotoxic damage
than those of controls. Further study of the relationship
between astrocytes and PC injury might be central to
understanding ET pathogenesis. Medications that in-
crease EAAT2, such as β-lactam antibiotics [45], might
be candidates for therapy for ET.Additional files
Additional file 1: Table S1. List of medications in essential tremor
patients.
Additional file 2: Figure S1. Specificity of EAAT1 antibody. EAAT1
antibody labeled a broad band of molecular weight around 64 kDa (A).
EAAT1 multimers and the differential glycosylated form of a higher
molecular weight could be occasionally seen (arrowheads, A). An alternative
spliced form of EAAT1 could be seen at 55 kDa. Pre-incubation of EAAT1
antibody with EAAT1 peptide abolished immunoreactive bands on Western
blot (A, left panel: EAAT1 antibody alone, right panel: EAAT1 antibody with
EAAT1 peptide block). Immunohistochemistry of EAAT1 in the cerebellar
cortex revealed immunoreactivity in the astrocytes mainly in the molecular
layer, and EAAT1 peptide block eliminated the immunoreactivity in an
adjacent paraffin-embedded section (B, upper panel: EAAT1 antibody
alone, lower panel: EAAT1 antibody with EAAT1 peptide block).
Additional file 3: Figure S2. Specificity of EAAT2 antibody. EAAT2
antibody labeled a strong band at the molecular weight of 55 kDa
(arrowhead, A). Faint multimers of EAAT2 of higher molecular weight can
also be observed (arrows, A). EAAT2 antibody also recognized the same
band in the human cerebral cortex in ET cases (B). Preincubation of EAAT2
antibody with EAAT2 peptide abolished the 55 kDa EAAT2 band (C, left
panel: EAAT2 antibody alone, right panel: EAAT2 antibody with EAAT2
peptide block). Immunohistochemistry of EAAT2 in the cerebellar cortex
revealed immunoreactivity in the astrocytes in the molecular and granular
cell layer and EAAT2 peptide diminished the immunoreactivity in an
adjacent paraffin-embedded section (D, left panel: EAAT2 antibody alone,
right panel: EAAT2 antibody with EAAT2 peptide block). Preincubation with
EAAT1 peptide with EAAT2 antibody did not eliminate the EAAT2
immunoreactivity in an adjacent paraffin-embedded section (E, left
panel: EAAT2 antibody alone, right panel: EAAT2 antibody with EAAT1
peptide block).
Additional file 4: Figure S3. EAAT2 levels and PC counts. EAAT2 levels
and PC counts of 16 ET cases and 13 controls were shown. Dots of different
colors represented different PC count tertiles. The bars represented the
mean of the EAAT2 levels in each tertile group.
Additional file 5: Figure S4. EAAT2 levels and rs3794087 genotypes.
We determined genotypes using frozen brain tissue of 16 ET cases and
13 controls, and the percentage of ET cases and controls with each
genotype is shown (A). Also, the number in each group is shown inside
each bar (A). ET cases had significantly decreased EAAT2 levels as compared
to controls in both GG and GT genotype groups (B). There were no controls
in the TT group, so no comparison was possible. Mean ± SEM were shown.Competing interests
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